title: Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy.
abstract: Breast cancer survivors are at increased risk for cognitive dysfunction, which reduces quality of life. Neuroimaging studies provide critical insights regarding the mechanisms underlying these cognitive deficits as well as potential biologic targets for interventions. We measured several metabolite concentrations using (1)H magnetic resonance spectroscopy as well as cognitive performance in 19 female breast cancer survivors and 17 age-matched female controls. Women with breast cancer were all treated with chemotherapy. Results indicated significantly increased choline (Cho) and myo-inositol (mI) with correspondingly decreased N-acetylaspartate (NAA)/Cho and NAA/mI ratios in the breast cancer group compared to controls. The breast cancer group reported reduced executive function and memory, and subjective memory ability was correlated with mI and Cho levels in both groups. These findings provide preliminary evidence of an altered metabolic profile that increases our understanding of neurobiologic status post-breast cancer and chemotherapy.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Rd., Stanford, CA, 94305-5795, USA, skesler@stanford.edu.
authors.forename: Shelli R
authors.initials: SR
authors.lastname: Kesler
authors.forename: Christa
authors.initials: C
authors.lastname: Watson
authors.forename: Della
authors.initials: D
authors.lastname: Koovakkattu
authors.forename: Clement
authors.initials: C
authors.lastname: Lee
authors.forename: Ruth
authors.initials: R
authors.lastname: O'Hara
authors.forename: Misty L
authors.initials: ML
authors.lastname: Mahaffey
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Wefel
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002794:Choline / Q000378:metabolism*; D003071:Cognition / Q000187:drug effects*; D005260:Female; D006801:Humans; D007294:Inositol / Q000378:metabolism*; D008875:Middle Aged; D017397:Prefrontal Cortex / Q000378:metabolism*; D016896:Treatment Outcome; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D007294:Inositol; D002794:Choline
references.citation: Neuroimage. 2011 Jul 1;57(1):69-75
references.pmid: 21349338
references.citation: Prog Brain Res. 2011;189:319-39
references.pmid: 21489397
references.citation: NMR Biomed. 2001 Jun;14(4):260-4
references.pmid: 11410943
references.citation: Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S15-21
references.pmid: 12973746
references.citation: Brain Behav Immun. 2013 Mar;30 Suppl:S99-108
references.pmid: 22884417
references.citation: Nat Rev Cancer. 2008 Nov;8(11):887-99
references.pmid: 18846100
references.citation: Breast Cancer Res Treat. 2007 Jul;103(3):303-11
references.pmid: 17009108
references.citation: J Clin Oncol. 2012 Jul 10;30(20):2500-8
references.pmid: 22665542
references.citation: Breast Cancer Res Treat. 2012 Apr;132(3):1099-106
references.pmid: 22205140
references.citation: BMC Neurol. 2012 May 28;12:28
references.pmid: 22632066
references.citation: Breast Cancer Res Treat. 2010 Oct;123(3):819-28
references.pmid: 20690040
references.citation: J Clin Oncol. 2012 Jan 20;30(3):274-81
references.pmid: 22184379
references.citation: Nat Rev Neurosci. 2007 Dec;8(12):921-34
references.pmid: 17971783
references.citation: Hum Brain Mapp. 2011 Aug;32(8):1206-19
references.pmid: 20669165
references.citation: Biol Psychiatry. 2003 Jun 1;53(11):1059-65
references.pmid: 12788251
references.citation: J Clin Exp Neuropsychol. 2009 Jan;31(1):73-89
references.pmid: 18608651
references.citation: Clin Cancer Res. 2009 Nov 1;15(21):6665-73
references.pmid: 19843664
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):70-85
references.pmid: 19657332
references.citation: Brain Behav Immun. 2013 Mar;30 Suppl:S109-16
references.pmid: 22698992
references.citation: J Clin Exp Neuropsychol. 2004 Oct;26(7):955-69
references.pmid: 15742545
references.citation: Br Med Bull. 2003;65:49-59
references.pmid: 12697616
references.citation: J Clin Oncol. 2010 Oct 10;28(29):4434-40
references.pmid: 20837957
references.citation: Cancer Treat Res. 2009;151:387-419
references.pmid: 19593525
references.citation: Diagn Interv Radiol. 2008 Dec;14(4):173-6
references.pmid: 19061159
references.citation: Front Behav Neurosci. 2012 Jun 13;6:24
references.pmid: 22707936
references.citation: Int Psychogeriatr. 2012 Jan;24(1):19-27
references.pmid: 21676281
references.citation: Microvasc Res. 2009 Mar;77(2):212-9
references.pmid: 19103208
references.citation: Neurobiol Aging. 2012 Mar;33(3):617.e1-9
references.pmid: 20739099
references.citation: Am J Med Genet A. 2009 Mar;149A(3):403-7
references.pmid: 19215057
references.citation: Cancer. 2004 Jun 1;100(11):2292-9
references.pmid: 15160331
references.citation: J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P19-27
references.pmid: 11773220
references.citation: J Natl Cancer Inst. 2002 Apr 17;94(8):592-7
references.pmid: 11959892
references.citation: Neuroscience. 2010 Mar 31;166(3):796-807
references.pmid: 20096337
references.citation: Brain Behav Immun. 2012 Feb;26(2):277-83
references.pmid: 21983278
references.citation: J Clin Oncol. 2006 Feb 1;24(4):675-80
references.pmid: 16446340
references.citation: J Clin Exp Neuropsychol. 2005 Jul;27(5):599-609
references.pmid: 16019636
references.citation: Neuropharmacology. 2011 Dec;61(8):1222-8
references.pmid: 21803055
references.citation: Brain Behav Immun. 2013 Mar;30 Suppl:S117-25
references.pmid: 22613170
references.citation: Cancer. 2010 Jul 15;116(14):3348-56
references.pmid: 20564075
references.citation: Curr Neurol Neurosci Rep. 2012 Jun;12(3):267-75
references.pmid: 22453825
references.citation: J Child Adolesc Psychopharmacol. 2009 Feb;19(1):51-9
references.pmid: 19232023
references.citation: AJNR Am J Neuroradiol. 1998 Feb;19(2):217-21
references.pmid: 9504468
references.citation: Coll Antropol. 2011 Jan;35 Suppl 1:159-62
references.pmid: 21648328
references.citation: Health Psychol. 2010 Jan;29(1):50-5
references.pmid: 20063935
references.citation: J Neurovirol. 2011 Feb;17(1):17-25
references.pmid: 21181521
references.citation: J Neurochem. 2007 Jan;100(1):191-201
references.pmid: 17227439
references.citation: Arch Neurol. 2011 Nov;68(11):1447-53
references.pmid: 22084128
references.citation: J Neurol Sci. 2011 Mar 15;302(1-2):49-57
references.pmid: 21195433
references.citation: Am J Physiol. 1998 Jan;274(1):C58-71
references.pmid: 9458713
references.citation: Hum Brain Mapp. 2012 Dec;33(12):2971-83
references.pmid: 22095746
references.citation: Breast Cancer Res Treat. 2012 Oct;135(3):799-809
references.pmid: 22918524
references.citation: Hum Brain Mapp. 2011 Mar;32(3):480-93
references.pmid: 20725909
references.citation: Curr Top Behav Neurosci. 2012;11:199-251
references.pmid: 22294088
references.citation: Breast Cancer Res Treat. 2009 Jul;116(1):113-23
references.pmid: 18629633
references.citation: Semin Oncol. 2011 Jun;38(3):431-8
references.pmid: 21600374
references.citation: Cancer. 2005 Nov 15;104(10):2222-33
references.pmid: 16206292
references.citation: Neurobiol Dis. 2012 Dec;48(3):329-38
references.pmid: 22820143
references.citation: Lancet Oncol. 2011 Jul;12(7):703-8
references.pmid: 21354373
references.citation: Neurobiol Dis. 2006 Jul;23(1):127-39
references.pmid: 16697651
references.citation: Neuropsychologia. 2009 Aug;47(10):2015-28
references.pmid: 19467352
references.citation: Int J Dev Neurosci. 2011 May;29(3):215-23
references.pmid: 21345366